State Street Corp Graphite Bio, Inc. Transaction History

State Street Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.24 - $2.66 $4,480 - $5,320	-2,000 Reduced 0.46%	434,467 $1.14 Million
Q3 2023 Nov 14, 2023	SELL	$2.18 - $2.77 $9,810 - $12,465	-4,500 Reduced 1.02%	436,467 $1.08 Million
Q2 2023 Aug 14, 2023	BUY	$2.47 - $3.38 $868,985 - $1.19 Million	351,816 Added 394.63%	440,967 $1.15 Million
Q4 2022 Feb 14, 2023	BUY	$2.82 - $3.59 $117,594 - $149,703	41,700 Added 87.88%	89,151 $295,000
Q2 2022 Aug 15, 2022	SELL	$2.14 - $5.23 $588,373 - $1.44 Million	-274,941 Reduced 85.28%	47,451 $130,000
Q1 2022 May 16, 2022	BUY	$5.1 - $13.06 $336,141 - $860,784	65,910 Added 25.7%	322,392 $1.64 Million
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $503,262 - $999,943	59,841 Added 30.43%	256,482 $3.19 Million
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $3.11 Million - $5.58 Million	196,641 New	196,641 $3.22 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.